Home > Journals > International Angiology > Past Issues > International Angiology 2000 March;19(1) > International Angiology 2000 March;19(1):35-8

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

INTERNATIONAL ANGIOLOGY

A Journal on Angiology


Official Journal of the International Union of Angiology, the International Union of Phlebology and the Central European Vascular Forum
Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,899


eTOC

 

ORIGINAL ARTICLES  


International Angiology 2000 March;19(1):35-8

language: English

Effects of bunazosin hydrochloride sustained-release formulation on cerebral circulation

Mochizuki Y., Oishi M., Takasu T.

From the Department of Neurology, Nihon University School of Medicine, Tokyo, Japan


Full text temporarily not available online. Contact us  


Background. We inves­ti­gat­ed the cere­bral blood flow in mild to mod­er­ate­ly hyper­ten­sive ­patients with chron­ic cere­bral infarc­tion ­before and after the admin­is­tra­tion of bunaz­o­sin hydro­chlo­ride sus­tained-­release for­mu­la­tion, a selec­tive sym­pa­thet­ic α1 recep­tor block­er.
Methods. Eleven mild to mod­er­ate­ly hyper­ten­sive ­patients (mean age 65.6 years) with chron­ic cere­bral infarc­tion were stud­ied. Interventions: The ­patients were on enal­a­pril ­maleate, an angio­ten­sin con­vert­ing ­enzyme inhib­i­tor, for one week and then enal­a­pril ­maleate was ­switched to bunaz­o­sin hydro­chlo­ride sus­tained-­release for­mu­la­tion. Measures: The cere­bral blood flow study was per­formed ­before and 8 weeks after start­ing the admin­is­tra­tion of bunaz­o­sin hydro­chlo­ride sus­tained-­release for­mu­la­tion. Cerebral blood flow was meas­ured using the ­stable xenon CT meth­od. The pic­ture anal­y­sis was per­formed using AZ-7000. The region­al cere­bral blood flow was meas­ured by plac­ing the ­region of inter­est on the CT imag­es. The region­al cere­bral blood flows were meas­ured ­before and 20 min­utes after intra­ve­nous injec­tion of 17 mg/kg acet­a­zol­a­mide.
Results. The blood flows in the parie­tal cor­tex and cau­date nucle­us 8 weeks after start­ing the admin­is­tra­tion of bunaz­o­sin hydro­chlo­ride sus­tained-­release for­mu­la­tion were sig­nif­i­cant­ly great­er than those ­before. The cereb­ro­vas­cu­lar acet­a­zol­a­mide reac­tiv­ity in the occip­i­tal cor­tex and cau­date nucle­us was sig­nif­i­cant­ly lower after switch­ing to bunaz­o­sin hydro­chlo­ride sus­tained-­release for­mu­la­tion than ­before.
Conclusions. Considering the ­reports that angio­ten­sin con­vert­ing ­enzyme inhib­i­tors show lit­tle influ­ence on cere­bral blood flow, the ­present study sug­gests that bunaz­o­sin hydro­chlo­ride sus­tained-­release for­mu­la­tion may show a good influ­ence on cere­bral blood flow in mild to mod­er­ate­ly hyper­ten­sive ­patients with chron­ic cere­bral infarc­tion.

top of page

Publication History

Cite this article as

Corresponding author e-mail